Riskpilot← Back to searchSign inGet full accessAREE Invest AB
ABActiveOrg 5592548092Vallavägen 26 AWholesale of pharmaceutical and medical goods · NACE 4646Est. 20200 employees
Revenue 2024
SEK 723K
+11950% vs 2023
EBITDA margin
99.9%
+1779% vs 2023
Equity ratio
72.5%
Financial strength
Net profit 2024
SEK 2,6M
+188% vs 2023
| Revenue | SEK 723K | +11950% |
| EBITDA | SEK 722K | +1779% |
| Net profit | SEK 2,6M | +188% |
| Total assets | SEK 4,9M | +33% |
| Equity | SEK 3,5M | +277% |
| Employees | 0 | — |
Legal name
AREE Invest AB
Org number
5592548092
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
6 maj 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska äga aktier och andelar i andra företag samt bedriva därmed förenlig verksamhet. Aktiebolaget ska bedriva handel med medicinsk utrustning (In Vitro Diagnostik) inom Sverige och internationellt.
Address
Vallavägen 26 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 75 | 94 | 6 | 723 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | 75 | 86 | −43 | 722 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 75 | 86 | −43 | 722 |
| Net financials | — | — | 200 | 946 | 2 003 |
| Profit before tax | 0 | 74 | 265 | 903 | 2 725 |
| Tax | −0 | −15 | −13 | −0 | −127 |
| Net profit | 0 | 59 | 252 | 903 | 2 598 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 25 | 100 | 404 | 3 677 | 4 881 |
| Equity | 25 | 84 | 336 | 939 | 3 538 |
| Long-term debt | 0 | 0 | 0 | 2 677 | 1 000 |
| Short-term debt | 0 | 15 | 47 | 40 | 323 |
| Total debt | — | 15 | 47 | 2 717 | 1 323 |
EBITDA margin
99.9%
This company
15.8%
Market median
+532% vs market
20202024
Equity ratio
72.5%
This company
38.2%
Market median
+90% vs market
20202024
Return on equity
73.4%
This company
18.4%
Market median
+299% vs market
20202024
Net profit margin
359.3%
This company
8.1%
Market median
+4336% vs market
20202024
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20202024
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-05-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PA | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AREE Invest AB 
DiaSystem Vet ABBoard members of AREE Invest AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pär Anders Tomas Claesson | Audit | 0 companies |
| Robert Kjell Rademacher | Board of Directors | 0 companies |
| Åsa Ingela Yvonne Andersson | Deputy Board Member | 0 companies |